AR029814A1 - MOLECULES MADE WITH CHORDIN 2 AND USES OF THE SAME - Google Patents
MOLECULES MADE WITH CHORDIN 2 AND USES OF THE SAMEInfo
- Publication number
- AR029814A1 AR029814A1 ARP010100994A ARP010100994A AR029814A1 AR 029814 A1 AR029814 A1 AR 029814A1 AR P010100994 A ARP010100994 A AR P010100994A AR P010100994 A ARP010100994 A AR P010100994A AR 029814 A1 AR029814 A1 AR 029814A1
- Authority
- AR
- Argentina
- Prior art keywords
- sec
- polypeptide
- nucleotide sequence
- sequences
- polypeptides
- Prior art date
Links
- 102000006533 chordin Human genes 0.000 title abstract 4
- 108010008846 chordin Proteins 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 15
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 15
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 15
- 239000002773 nucleotide Substances 0.000 abstract 10
- 125000003729 nucleotide group Chemical group 0.000 abstract 10
- 101150032497 CHRDL2 gene Proteins 0.000 abstract 4
- 102100032766 Chordin-like protein 2 Human genes 0.000 abstract 4
- 108020004414 DNA Proteins 0.000 abstract 4
- 230000000295 complement effect Effects 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- -1 antibodies Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000007045 gastrulation Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Moléculas de ADN aisladas que codifican polipéptidos emparentados con Chordin 2 (CHL2). El CHL2 relaciona estructuralmente con el inhibidor de proteínas morfogenéticas oseas (BMP) conocido como Chordin (CHD) o gastrulacion corta (SOG). Una molécula aislada de ácido nucleico que comprende una secuencia nucleotídica seleccionada del grupo y que consta de: a) la secuencia nucleotídica segun se establece en la SEC. con N. de ID: 1 o con N. de ID: 4; b) la secuencia nucleotídica del inserto de ADN en cualquier de los numeros de deposito ATCC PTA û 1479 O PTA û 1480; c) una secuencia nucleotídica que codifique el polipéptido segun se establece en la SEC con N. de ID: 2 o SEC con N. de ID: 5; d) una secuencia nucleotídica que hibridiza con el complemento de cualquiera de las secuencias a) ûc); e) una secuencia complementaria a cualquiera de las secuencias a) a c), donde las secuencias son como se describen en la memoria descriptiva. Una molécula aislada de ácido nucleico que comprende una secuencia nucleotídica seleccionada del grupo y que consta de una secuencia nucleotídica que codifica un polipéptido que es al menos 70% idéntico y que tiene la actividad establecida para los polipéptidos de SEC con N. de ID: 2 o 5, una secuencia nucleotídica que codifica una variante alélica o de union de la secuencia establecida en la SEC con N. de ID: 1 o SEC con N. de ID: 4, la secuencia del inserto de ADN con cualquiera de los numeros de deposito ATCC PTA 1479 o PTA 1480 o una region de dichas secuencias que codifica un fragmento de polipéptido de al menos 25 residuos de aminoácidos que tiene la actividad establecida para los polipéptidos de SEC con N. de ID: 2 o 5 o es antigénico, y secuencias nucleotídicas que hibridizan o son complementarias de las mismas. Una molécula de ácido nucleico seleccionada del grupo y que consta de una secuencia nucleotídica que codifique un polipéptido segun se establece en la SEC con N. de ID: 2 o SEC con N. de ID: 5 con al menos una sustitucion conservadora, insercion, deteccion, truncacion de terminal C y/o N de aminoácidos, en que el polipéptido codificado tiene una actividad de polipéptido segun lo establecido en la SEC con N. de ID: 2 o SEC con N. de ID: 5, secuencias nucleotídicas de las mismas que contengan un fragmento de al menos 16 nucleotidos, que hibridicen o complementarias de las mismas. Polipéptidos aislados que comprenden la secuencia de aminoácidos de cualquier de las secuencias SEC con N. de ID: 2 o SEC con N. de ID: 5 ortologos, fragmentos variantes y derivados que tienen al menos una actividad del polipéptido segun lo establecido en la SEC con N. de ID: 2 o SEC con N. de ID: 5. Agentes de enlace, anticuerpos, vectores, células huésped y métodos para producir polipéptidos CHL2. Una hibridoma que produce un agente selectivo capaz de ligarse con un polipéptido de acuerdo con lo definido más arriba. Composiciones y métodos farmacéuticos y de diagnostico. Un método para tratar, prevenir o mejorar enfermedades que se relacionen con polipéptidos CHL2. Dispositivo que incluye una membrana y cápsulas encapsuladas de la misma capaces de secretar una proteína como las ya definidas. Método de modulacion de niveles de polipéptido en un animal que incluye la administracion de moléculas de ADN como las definidas.Isolated DNA molecules encoding polypeptides related to Chordin 2 (CHL2). CHL2 is structurally related to the bone morphogenetic protein (BMP) inhibitor known as Chordin (CHD) or short gastrulation (SOG). An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group and consisting of: a) the nucleotide sequence as set forth in the SEC. with N. of ID: 1 or with N. of ID: 4; b) the nucleotide sequence of the DNA insert in any of the ATCC tank numbers PTA û 1479 or PTA û 1480; c) a nucleotide sequence encoding the polypeptide as set forth in the SEC with N. of ID: 2 or SEC with N. of ID: 5; d) a nucleotide sequence that hybridizes with the complement of any of the sequences a) ûc); e) a sequence complementary to any of the sequences a) to c), where the sequences are as described in the specification. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group and consisting of a nucleotide sequence encoding a polypeptide that is at least 70% identical and has the activity established for SEC polypeptides with N. of ID: 2 or 5, a nucleotide sequence encoding an allelic or binding variant of the sequence established in the SEC with N. of ID: 1 or SEC with N. of ID: 4, the sequence of the DNA insert with any of the numbers of ATCC deposit PTA 1479 or PTA 1480 or a region of said sequences encoding a polypeptide fragment of at least 25 amino acid residues having the activity established for SEC polypeptides with N. of ID: 2 or 5 or is antigenic, and nucleotide sequences that hybridize or are complementary to them. A nucleic acid molecule selected from the group and consisting of a nucleotide sequence encoding a polypeptide as set out in the SEC with N. of ID: 2 or SEC with N. of ID: 5 with at least one conservative substitution, insertion, detection, truncation of terminal C and / or N amino acids, in which the encoded polypeptide has a polypeptide activity as established in the SEC with N. of ID: 2 or SEC with N. of ID: 5, nucleotide sequences of the same that contain a fragment of at least 16 nucleotides, which hybridize or complement them. Isolated polypeptides comprising the amino acid sequence of any of the sequences SEC with N. of ID: 2 or SEC with N. of ID: 5 orthologs, variant fragments and derivatives having at least one activity of the polypeptide as established in the SEC with N. of ID: 2 or SEC with N. of ID: 5. Binding agents, antibodies, vectors, host cells and methods for producing CHL2 polypeptides. A hybridoma that produces a selective agent capable of binding with a polypeptide as defined above. Compositions and pharmaceutical and diagnostic methods. A method to treat, prevent or improve diseases that are related to CHL2 polypeptides. Device that includes a membrane and encapsulated capsules thereof capable of secreting a protein such as those already defined. Method of modulation of polypeptide levels in an animal that includes the administration of DNA molecules as defined.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18646200P | 2000-03-02 | 2000-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029814A1 true AR029814A1 (en) | 2003-07-16 |
Family
ID=22685056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100994A AR029814A1 (en) | 2000-03-02 | 2001-03-02 | MOLECULES MADE WITH CHORDIN 2 AND USES OF THE SAME |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1266000A1 (en) |
| JP (1) | JP2003525611A (en) |
| AR (1) | AR029814A1 (en) |
| AU (2) | AU4196801A (en) |
| CA (1) | CA2401175A1 (en) |
| MX (1) | MXPA02008506A (en) |
| WO (1) | WO2001064885A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000032773A1 (en) | 1998-11-27 | 2000-06-08 | Darwin Discovery Ltd. | Compositions and methods for increasing bone mineralization |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP1303605A2 (en) * | 2000-07-19 | 2003-04-23 | Eli Lilly And Company | Nucleic acids, vectors, host cells, polypeptides, and uses thereof |
| ATE369563T1 (en) * | 2000-12-28 | 2007-08-15 | Shionogi & Co | CHORDIN-LIKE POLYPEPTIDES AND THEIR DNA |
| JP2005253301A (en) * | 2002-02-20 | 2005-09-22 | Taisho Pharmaceut Co Ltd | Protein having bone morphogenetic protein binding region and gene encoding the same |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| JP2006515753A (en) * | 2002-08-07 | 2006-06-08 | キュラジェン コーポレイション | Therapeutic polypeptides, nucleic acids encoding the same, and methods of use |
| WO2004082608A2 (en) * | 2003-03-14 | 2004-09-30 | Celltech R & D, Inc. | Ligands for tgf-beta binding proteins and uses thereof |
| EA015166B1 (en) | 2003-06-16 | 2011-06-30 | Ю-Си-Би Мэньюфэкчуринг, Инк. | Immunogen sclerostin peptides (sost), inducing formation of specific antibodies |
| WO2005014817A2 (en) * | 2003-08-07 | 2005-02-17 | Compugen Ltd. | Chordin-like homologs |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CL2008002775A1 (en) | 2007-09-17 | 2008-11-07 | Amgen Inc | Use of a sclerostin binding agent to inhibit bone resorption. |
| SMT202000095T1 (en) | 2010-05-14 | 2020-03-13 | Amgen Inc | High concentration anti-sclerostin antibody formulations |
| US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
| MA35009B1 (en) | 2011-03-25 | 2014-04-03 | Amgen Inc | ANTI-SCLERROTIN ANTIBODY CRYSTALS AND FORMULATIONS THEREOF |
| US10538584B2 (en) | 2011-08-04 | 2020-01-21 | Amgen Inc. | Methods for treating bone gap defects |
| EA036740B1 (en) | 2011-12-28 | 2020-12-15 | Эмджен Инк. | Method of increasing alveolar bone height through the use of anti-sclerostin antibodies |
| US9925260B2 (en) | 2012-07-05 | 2018-03-27 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
| MA41142A (en) | 2014-12-12 | 2017-10-17 | Amgen Inc | ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| SG11202008206TA (en) | 2018-03-30 | 2020-09-29 | Amgen Inc | C-terminal antibody variants |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19817946A1 (en) * | 1998-04-17 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | New nucleic acid sequences expressed in normal uterine tissues, and derived polypeptides, for treatment of uterine cancer and identification of therapeutic agents |
| AU5475199A (en) * | 1998-08-10 | 2000-03-06 | Genetics Institute Inc. | Human chordin-related proteins and polynucleotides encoding them |
| CA2339043A1 (en) * | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| CA2387810A1 (en) * | 1999-10-18 | 2001-04-26 | Lexicon Genetics Incorporated | Novel human proteins and polynucleotides encoding the same |
| EP1230359A1 (en) * | 1999-11-10 | 2002-08-14 | Compugen Ltd. | Chordin-like homologs |
-
2001
- 2001-03-02 AU AU4196801A patent/AU4196801A/en active Pending
- 2001-03-02 WO PCT/US2001/006891 patent/WO2001064885A1/en not_active Ceased
- 2001-03-02 AR ARP010100994A patent/AR029814A1/en not_active Application Discontinuation
- 2001-03-02 MX MXPA02008506A patent/MXPA02008506A/en not_active Application Discontinuation
- 2001-03-02 CA CA002401175A patent/CA2401175A1/en not_active Abandoned
- 2001-03-02 JP JP2001564368A patent/JP2003525611A/en active Pending
- 2001-03-02 EP EP01913290A patent/EP1266000A1/en not_active Withdrawn
- 2001-03-02 AU AU2001241968A patent/AU2001241968B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU4196801A (en) | 2001-09-12 |
| AU2001241968B2 (en) | 2005-09-15 |
| WO2001064885A1 (en) | 2001-09-07 |
| EP1266000A1 (en) | 2002-12-18 |
| MXPA02008506A (en) | 2002-12-13 |
| CA2401175A1 (en) | 2001-09-07 |
| JP2003525611A (en) | 2003-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029814A1 (en) | MOLECULES MADE WITH CHORDIN 2 AND USES OF THE SAME | |
| EP1548032A4 (en) | KDR PEPTIDES AND VACCINES CONTAINING THEM | |
| AR039003A1 (en) | COMPOSITIONS AND METHODS TO ALTER THE CONTENT OF TOCOTRIENOLES | |
| AR066201A2 (en) | OPTIMIZED POLINUCLEOTIDES FOR EXPRESSION IN PLANTS THAT CODIFY PESTICIDE PROTEINS, AND METHOD FOR CONTROLLING A PLANT PEST | |
| IL220133A0 (en) | Nucleic acid molecules and recombinant vaccines comprising sequences encoding immunogens and immunomodulators, compositions comprising said nucleic acid molecules, and uses of said nucleic acid molecules, recombinant vaccines, compositions and immunogens and immunomodulators in the preparation of medicaments and as medicaments | |
| BR9712348A (en) | isolated polynucleotide molecule, expression vector, cultured cell into which an expression vector was introduced, process to produce an isolated fgf homologous polypeptide, isolated fgf homologous polypeptide, pharmaceutical composition, antibody, processes to stimulate ex vivo myocyte progenitor cells, and, paralyzing an agent or drug selectively for heart tissue. | |
| BR0108959A (en) | Improved poloxamer or poloxamine compositions for nucleic acid delivery | |
| AR065289A1 (en) | ACTIVINA ANTAGONISTS - ACTRIA AND ITS USES FOR THE PROMOTION OF OSEO GROWTH AND MULTIPLE MYELOMA TREATMENT | |
| AR010124A1 (en) | NUCLEIC ACID MOLECULA CODING A SUCROSE-FRUCTOSILTRANSFERASE, VECTOR CONTAINING IT, HOSPITAL CELL TRANSFORMED WITH SAME, SACAROSA-FRUCTOSIL TRANSFERASA CODIFICATION FOR SUCH MOLECULA AND PROCEDIFICATION | |
| CO5700785A2 (en) | NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCAL DISEASE | |
| ES2170065T3 (en) | MODULATION OF PROTEIN KINASE C BY OLIGONUCLEOTIDES. | |
| BR9809914A (en) | Lactoferrin receptor moracella genes | |
| KR960706559A (en) | BMP-12, BMP-13 and dry-derived compositions thereof (BMP-12, BMP-13 ANDTENDON-INDUCING COMPOSITIONS THEREOF) | |
| DARMER et al. | Three different prohormones yield a variety of Hydra-RFamide (Arg-Phe-NH2) neuropeptides in Hydra magnipapillata | |
| PE20240915A1 (en) | COMPOSITIONS AND METHODS FOR TREATING FABRY DISEASE | |
| CA2522994A1 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
| ES2212930T1 (en) | THERAPEUTIC USE OF RANK ANTAGONISTS. | |
| ES2663242T3 (en) | Gene products differentially expressed in tumors and their use | |
| FR2726472B1 (en) | CARRIER WITH ADJUVANT EFFECT, IMMUNOGENIC COMPLEX CONTAINING THE SAME, PREPARATION METHOD THEREOF, NUCLEOTIDE SEQUENCE AND VACCINE | |
| EP0232523A3 (en) | Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins | |
| RU2008125041A (en) | siRNA AGAINST MYOSIN VA AND DEPIGMENTATION OF SKIN | |
| Flitman-Tene et al. | Variable lipoprotein genes of Mycoplasma agalactiae are activated in vivo by promoter addition via site-specific DNA inversions | |
| Coe et al. | Characterization of the Pacific salmon gonadotropin-releasing hormone gene, copy number and transcription start site | |
| AR010337A1 (en) | ISOLATED NUCLEIC ACID, NUCLEIC ACID MOLECULA, PROBE, RECOMBINANT EXPRESSION VECTOR, CELL, METHOD FOR PRODUCING A POLYPEPTIDE OF H.PYLORI, METHOD FOR DETECTING THE PRESENCE OF A NUCLEIC ACID HELICOBACTER, POLIPE FORMULATION FOR VACCINE | |
| CO5280153A1 (en) | ANTIGEN ASSOCIATED WITH TUMORS (R11) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |